General Law Committee
JOINT FAVORABLE REPORT
AN ACT REQUIRING PHARMACISTS TO INCLUDE MANUFACTURER NAMES AND MEDWATCH REPORTING INFORMATION ON GENERIC DRUG CONTAINERS.
Joint Favorable Substitute
SPONSORS OF BILL:
Sen. Joseph J. Crisco, 17th Dist. (Co-Sponsor)
REASONS FOR BILL:
This bill would require each pharmacist to include the quantity of the prescribed drug placed in each container and a prominently displayed expiration date based on the manufacturers recommended conditions of use and storage displayed in layman's terms on each prescription container.
S.B. 28 is also the PHARMACY bill bundle package and contains the following bills within it:
● SB 933: TO MAKE LICENSING & LICENSE RENEWAL FOR PRACTITIONERS WHO DISTRIBUTE, ADMINISTER OR DISPENSE CONTROLLED SUBSTANCES CONTINGENT ON REGISTRATION IN THE ELECTRONIC PRESCRIPTION DRUG MONITORING PROGRAM.
● HB 6918: TO INCREASE HEALTH CARE TRANSPARENCY BY REQUIRING PRESCRIBER CONSENT AND A MEDICAL BASIS PRIOR TO ANY CHANGE IN THE PRESCRIPTION DRUG DISPENSED TO CERTAIN PATIENTS.
***Substitute Language as contained in LCO # 5204, modifies the bill as follows:
Section 20-617 of the general statutes is repealed and the following is substituted in its place:
(b) In addition to the information required to be included on the 11 label of each prescription container pursuant to subsection (a) of this 12 section, each pharmacist shall include on the label of each prescription 13 container for a drug sold only by generic name, as defined in section 14 20-14a, and not by brand name, as defined in said section: (1) The 15 name of the manufacturer of the generic drug placed in the container, 16 and (2) the Internet web site and toll-free telephone number for the United States Food and Drug Administration's safety information and 18 adverse event reporting program (MedWatch).
Section 21a-317 of the general statutes is repealed and the following is substituted in its place:
(b) The commissioner shall not issue or renew a license of a 31 practitioner who distributes, administers or dispenses any controlled 32 substance or who proposes to engage in distributing, prescribing, 33 administering or dispensing any controlled substance within this state 34 unless such practitioner has obtained a certificate of registration and 35 registered for access to the electronic prescription drug monitoring 36 program established pursuant to subsection (j) of section 21a-254.
RESPONSE FROM ADMINISTRATION/AGENCY:
Sheila Matthews, Cofounder of AbleChild.org
AbleChild.org requests an amendment to S.B. 28 to include that all prescription drug labels and containers include the 1-800 MedWatch phone number so that consumers (and all who have direct contact with the products) have immediate access to the “adverse drug reaction” reporting system regardless of whether the drug is brand name or generic.
NATURE AND SOURCES OF SUPPORT:
NATURE AND SOURCES OF OPPOSITION:
Reported by: Jason Snukis
Date: March 17, 2015